Amendments t the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 9. (Cancelled)

10. (Currently amended) A method of treating a subject suffering from a condition that is characterized by high human tissue glucuronidase activity, the method comprising administering to the subject a glucuronidase inhibitor selected from the group consisting of verapamil and verapamil derivatives, together with a suitable pharmacologically compatible adjuvant**,**

wherein the verapamil and verapamil derivatives are selected from the group consisting of the R-enantiomer of verapamil; metabolites of R-verapamil; chemically substituted derivatives of R-verapamil; R-gallopamil; and its metabolites or its salts with pharmacologically compatible acids.

11. (Cancelled)

12. (Previously presented) The method according to claim 10, wherein the condition is tumor progression or metastasis formation.

13. (Previously presented) The method according to claim 10, wherein the condition is toxicity or side effects arising from metabolically-formed glucuronide conjugates of side-effect-rich active materials.

14. (Previously presented) The method according to claim 10, wherein the glucuronidase inhibitor and pharmacologically compatible adjuvant are administered to the subject in a normal or controlled release form.

15. (Currently amended) The method according to claim 10, ~~**wherein the pharmacologically compatible adjuvant is**~~ **further comprising administering** a glucuronide conjugate of an inflammation-inhibiting active material.

16. (Previously presented) The method according to claim 15, wherein the condition is located in the intestine of the subject.

17. (Previously presented) A method of selectively activating a glucuronide prodrug in a target tissue, wherein glucuronidase is present in the target tissue, comprising administering to a subject a glucuronidase inhibitor, glucuronide prodrug, and glucuronidase bound to a target tissue-specific substance, whereby the glucuronide prodrug is activated in the target tissue.

18. (Previously presented) The method according to claim 17, wherein the target tissue-specific substance is selected from the group consisting of antibodies, proteins, and liposomes.

19. (New) A method of inhibiting human tissue glucuronidase comprising orally or parenterally administering to the human a glucuronidase inhibitor selected from the group consisting of verapamil and verapamil derivatives, together with a suitable pharmacologically compatible adjuvant,

wherein the verapamil and verapamil derivatives are selected from the group consisting of the R-enantiomer of verapamil; metabolites of R-verapamil; chemically substituted derivatives of R-verapamil; R-gallopamil; and its metabolites or its salts with pharmacologically compatible acids.

20. (Cancelled)